Cardiovascular disease (CVD) is one of the most common public health challenges worldwide. The World Health Organization (WHO) estimates that the cost of not investing in CVD prevention and therapy could amount to as much as \$47 trillion worldwide in the next 25 years[@b1], and the consequences will be more severe in developing countries, given that 80% of cardiovascular deaths occur in low and middle income countries[@b1]. As a major risk factor for cardiovascular disease, hypertension is the most common chronic condition in American adults. Recent studies have shown that two thirds of hypertensives in the United States are undertreated or untreated[@b2]. It has been demonstrated that even people who are free of hypertension (BP \< 140/90 mm Hg) at the age of 55 have a 90% lifetime risk for developing hypertension, according to the Framingham data[@b3]. In addition, accumulating evidence suggest that health-promoting lifestyle modifications can improve blood pressure (BP) control and even reduce medication needs[@b4]. Among the comprehensive lifestyle modifications, dietary adjustment is one of the most effective measures for preventing hypertension. A previous meta-analysis suggested that even small changes in BP caused by dietary modification might have a significant impact on the prevalence of hypertension[@b5].

Green tea, derived from the plant Camellia sinensis, is a popular beverage worldwide and the major source of flavonoid intake in the US diet[@b6]. The most prominent effects of tea on human health have been attributed to green tea, and the health-promoting effects of green tea are mainly attributed to catechins, which belong to a family of compounds known as flavonoid-like polyphenols or flavanols[@b7]. A recent meta-analysis has revealed that green tea consumption might significantly reduce plasma low density lipoprotein--cholesterol (LDL-C) and total cholesterol concentrations[@b8]. In addition, our previous meta-analysis demonstrated that green tea may have a favorable effect on glucose control in adults[@b9]. Therefore, one question is pertinent: does green tea also have beneficial effects on BP? Although Hartley et al. conducted a meta-analysis evaluating the effect of green tea on BP, they only included two RCTs when evaluating the effect of green tea on BP[@b10], and thus the results of their study might be interpreted with caution. To date, previous randomized controlled trials (RCTs) investigating the effects of green tea consumption on BP have generated inconsistent results. Thus, we conducted the meta-analysis to explore the effects of green tea on BP based on the PRISMA guidelines.

Results
=======

Results of the literature search
--------------------------------

Detailed processes of the relevant study selection are shown in [Fig. 1](#f1){ref-type="fig"}. A total of 186 reports were initially identified, and 153 articles were excluded either because of duplication or because they were clearly not relevant to the current meta-analysis after carefully reviewing the titles and abstracts. Thus, 33 articles remained for an in-depth examination. Among these 33 articles, 20 were further excluded for the following reasons: 8 were due to their short duration (\<1 day), 6 were due to no data of SBP or DBP, and 6 were discarded because the green tea extract was given as part of a multi-component supplement. Thus, 13 articles were ultimately selected for inclusion in the meta-analysis[@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23].

Study characteristics
---------------------

A summary of the study characteristics included in the meta-analysis is presented in ([Table 1](#t1){ref-type="table"}). The total number of subjects included in each study ranged from 22 to 240 subjects. The study duration varied from 3 wk to 3 mo (median: 12 wk). Of the 13 trials included in the current meta-analysis, 9 trials focused on adults with prehypertension, 3 trials selected participants with stage 1 hypertension and one trial investigated subjects with Stage 2 hypertension. Most studies (11 of 13) used parallel design. All studies suggested subjects maintain a usual diet, and one study recommended that subjects maintain their physical activities during the study period. Of the 9 studies ruled out the confounding effect of caffeine on BP, 5 used decaffeinated green tea extract as supplements, 2 used decaffeinated green tea beverage in the intervention group, and 2 used placebo matching caffeine in the control group. And four studies used caffeinated green tea as supplements. The green tea polyphenols content ranged from 208 to 1207 mg/d (median: 582.8 mg/d).

Data quality
------------

Study quality was assessed by using the Jadad scale and the results were varied. Five trials[@b18][@b19][@b21][@b22][@b23] were classified as high quality (Jadad score of ≥4) and the remaining 8 trials were low quality (Jadad score of \<4). All of the high-quality RCTs reported the use of random number generation or randomization list performed by an independent statistician, and 2 studies used an adequate allocation concealment conducted by a third-party manufacture. Details related to the dropouts were reported in all high quality trials.

Effect of green tea consumption on blood pressure
-------------------------------------------------

As shown in [Fig. 2](#f2){ref-type="fig"}, a significant reduction in SBP was observed in subjects supplemented with green tea (−1.98 mmHg; 95% CI, −2.94 to −1.01 mmHg; *P* \< 0.001) when compared with control subjects. The mean difference in DBP was reported in 13 trials and was found to be significantly different (−1.92 mmHg; 95% CI, −3.17 to −0.68 mmHg; *P* = 0.002; [Fig. 3](#f3){ref-type="fig"}). In addition, no significant differences were detected when we used the different model to pooling the data ([Supplementary Fig. S1 and Fig. S2](#s1){ref-type="supplementary-material"} online).

We performed the subgroup analyses ([Table 2](#t2){ref-type="table"}) to further explore the effects of BP status, study design, green tea polyphenols dose, study duration and quality as well as to evaluate any differences between trials by ruling out confounding effect of caffeine and using caffeinated green tea as supplement. No significant differences were found between the random-effects model and fixed-effects model in the subgroup analyses. Green tea polyphenols consumption was categorized as either high-dose (≥582.8 mg/d) or low-dose (\<582.8 mg/d). The duration was divided into a long-term subgroup (≥12 wk) and a short-term subgroup (\<12 wk). The subgroup analyses indicated that green tea significantly lowered BP in subjects with Stage 1 hypertension or prehypertension. In parallel- and crossover-design subgroups, significant reductions in BP were observed in the parallel-design subgroup. However, no significant effect was found in the crossover-design subgroup. When we stratified studies according to the type of intervention, the beneficial effects of green tea on BP could only be observed when the confounding effect of caffeine was removed. Significant reductions in SBP and DBP were only observed in the low-dose green tea polyphenols subgroup or the long-term duration subgroup. Finally, when studies were stratified according to Jadad score, significant reductions of BP were found only in those trials with high Jadad scores.

The results of meta-regression analysis did not observe a significant dose-responsive effect between green tea and SBP (*P* for trend = 0.14) or DBP (*P* for trend = 0.16). And the sensitivity analyses showed that the pooled effects of green tea on BP were not altered when the analyses were limited to high-quality studies and after imputation using a correlation coefficient of 0.5. Moreover, systematically removing each trial during the sensitivity analyses did not significantly change the overall observed effects of green tea on BP.

Publication bias
----------------

Funnel plots ([Supplementary Fig. S3 and Fig. S4](#s1){ref-type="supplementary-material"} online) and Egger\'s tests showed no significant publication bias in the current meta-analyses of SBP and DBP (Egger\'s test: *P* = 0.62 and 0.81).

Discussion
==========

Our meta-analysis showed that green tea consumption significantly lowered BP and this effect was not altered when we pooled the data according to BP status. Significant reductions in SBP and DBP were only observed in the low-dose green tea polyphenols, the long-term duration, parallel-design RCTs, high-quality trials subgroups or when the confounding effect of caffeine was removed.

A previous meta-analysis of observational studies demonstrated that 1 cup/d of green tea was associated with a 10% decrease in the risk of developing coronary artery diseases[@b24]. A large population-based, prospective cohort study also found that an average of 2 cups/d of green tea intake significantly decreased the mortality risk of CVD[@b25]. The overall result of the current meta-analysis and its subgroup analyses consistently suggested that green tea had a significant lowering effect on BP, which might partially explain the favorable effects of green tea on CVD.

Consistent with this meta-analysis, a recent meta-analysis also found that green tea consumption could improve both SBP and DBP control[@b26]. Another meta-analysis suggested that green tea intervention had a favorable effect on SBP, but failed to lower the DBP level[@b27]. Contrary to the two studies, this meta-analysis improved the design of the subgroup analyses and investigated the potential influence of more confounding factors such as caffeine, intervention duration of green tea consumption, and study quality on the overall results of the meta-analysis. Our subgroup analyses showed that green tea consumption significantly decreased BP in subjects with Stage 1 hypertension or prehypertension, and the beneficial effects of green tea on lowering BP were more prominent in subjects with Stage 1 hypertension. In addition, the subgroup analyses based on the parallel-design RCTs and high-quality study indicated that green tea has a significant lowering effect on BP. Consistent with the study, *in vivo* studies have revealed that green tea extract can significantly reduce the increase of BP and enhance endothelial function in hypertensive rats[@b28][@b29][@b30]. The mechanism underlying the beneficial effect of green tea on BP control may involve the following aspects: 1) Green tea extract can maintain vascular tone by balancing vasoconstricting substances, including angiotensin II (Ang-II), prostaglandins, endothelin-1 (ET-1), and vasodilating substances, such as prostacyclin and various endothelium-derived hyperpolarizing factors (EDHFs)[@b31][@b32][@b33][@b34]. 2) Green tea can improve ventricular function and exert beneficial effects via increasing nitric oxide (NO) production from endothelium in PI3-kinase dependent pathways[@b29]. Green tea extract is also capable of regulating eNOS activation and ROS production, thereby increasing the production of NO[@b35]. 3) Green tea is able to reduce oxidative stress and manage the generation of ROS by inhibiting pro-oxidant enzymes and inducing antioxidant enzymes. Green tea catechins also function circuitously by inhibiting the nuclear factor-kappa B, redox-sensitive transcription factors, and activator protein-1 responsible for oxidative stress[@b36][@b37][@b38]. Moreover, green tea catechins can induce an anti-inflammatory effect by suppression of several inflammatory factors, such as cytokines, adhesion molecules, and nuclear factor-kappa B[@b35][@b39].

We observed a significant reduction of SBP and DBP in the studies with a low-dose green tea polyphenols consumption subgroup and the subgroup of long-term intervention. Meanwhile, our study indicates that green tea intake has a significant lowering BP effect only in the trials designed to rule out the confounding effects of caffeine when we stratify the studies according to the type of intervention. This finding may partially explain why a high-dose of green tea consumption did not reduce BP, since a higher dose of green tea contains more caffeine and regular caffeine intake might increase BP, as reported by Noordzij et al[@b40] in their meta-analysis. Additionally, a previous cohort study including 1017 US males with a median age of 33 years suggested that drinking coffee was associated with BP increase and the risk of hypertension[@b41]. Despite its potential BP-increasing effect, coffee drinking appeared not to be related to coronary events in a prospective study that included over 45 000 US male[@b42]. Therefore, the effects of high-dose green tea containing caffeine on cardiovascular disease events need to be further evaluated by more high-quality and large sample size studies. Finally, a significant reduction in BP was found in the high Jadad score subgroup that possessed less bias, but was not shown in the low Jadad score subgroup.

Although the relatively larger number of pooled participants provides stronger statistical power to evaluate the treatment effect, this meta-analysis has several inevitable limitations. First, of the 13 studies, 5 studies were high-quality RCTs, whereas the remaining 8 studies were of low quality. The slight inconsistent results of the subgroup analyses conducted to explore the effects of green tea on BP may be attributed to the differences in study quality and an overall limited number of high-quality studies. The 2010 Consolidated Standard of Reporting Trials (CONSORT) is used worldwide to improve the reporting of RCTs, and also provides the professional guidance on the study design and conducting[@b43]. To improve the study qualities, future RCTs should be conducted in accordance with the CONSORT statement, and particularly provide the enough information on the five items in Jadad scoring criterion which are essential for subsequent quality evaluation in the meta-analysis. Second, BP was not the primary outcome in part of the RCTs selected in this meta-analysis and the null findings of secondary outcomes may not be published. Third, the results of meta-regression analysis did not show a significant dose-responsive effect between green tea and SBP or DBP. Therefore, it is difficult to determine the optimal dose for a dietary program as part of a health policy aimed at improving hypertension health. In addition, most of the selected studies (11 of 13) did not report the information on sample size calculation. We could not directly evaluate the rationality of sample sizes in these studies, because the appropriate sample size for the RCT is based on the power calculation, α value, SD value and expected difference according to the specific study design[@b44]. The investigators should properly calculate sample sizes before starting the future RCTs and report the details in the publication.

In conclusion, this meta-analysis indicates that green tea consumption significantly lowers BP. The significant decrease of BP in low-dose green tea subgroup, long-term intervention duration subgroup or the subgroup ruling out the confounding effects of caffeine needs to be evaluated by more high-quality RCTs specifically designed to evaluate the effects of green tea on BP.

Methods
=======

Search strategy
---------------

PubMed (updated to March 2014; <http://www.ncbi.nlm.nih.gov/pubmed/>), Embase (updated to March 2014; <http://www.embase.com/>), the Cochrane Library (updated to March 2014; <http://www.cochrane.org/>) database, and reference lists and reviews were searched for RCTs examining the effects of green tea on BP in humans. The structured search strategies used the following terms: green tea, green tea extract, catechin, catechins, EGCG, camellia sinensis, or tea polyphenols \[All Fields\] which were paired with blood pressure \[All Fields\]. The searching was restricted to the reports of randomized controlled trials conducted in human subjects.

Study selection
---------------

Studies were included in the meta-analysis if they met the following criteria: 1) subjects ingested green tea beverage or extract for ≥1 wk; 2) the study was a RCT conducted in human subjects with either a parallel or crossover design; 3) the baseline and endpoint values for systolic blood pressure (SBP), diatolic blood pressure (DBP), or their difference with either SD, SEM or 95% CI were available for each group in the study; 4) the green tea or green tea extract was not given as part of a multi-component supplement; 5) the study used a concurrent control group for green tea or green tea extract treatment group and the only difference between the control and treatment group was green tea or green tea extract.

Data extraction and quality assessment
--------------------------------------

The data were collected by using a standardized and pre-piloted data extraction form that included the following categories: 1) study characteristics including authors, publication year, sample size, study design, study duration, dose, type of intervention and type of diet; 2) population information including age and baseline health status; and 3) net changes in SBP or DBP.

The quality of RCTs was evaluated by using the following criteria: 1) randomization (the study was described as randomized); 2) double blinding (participant masking and researcher masking); 3) reporting the number of withdrawals and reasons for withdrawal; 4) allocation concealment; and 5) generation of random numbers (using computer, random numbers table, shuffled cards or tossed coins, etc). RCTs scored one point for each area addressed in the study design with a possible score ranging between 0 and 5 (highest level of quality)[@b45]. The studies that received a score of ≥4 were deemed to be of high quality, whereas those that received a score of \<4 were considered low quality.

Statistical analysis
--------------------

Our meta-analysis was performed using STATA (Version 11; StataCorp, College Station, TX). The treatment effects were defined as weighted mean difference and 95% CIs calculated for net changes in BP values. The statistic heterogeneity was assessed by using Cochran\'s test (*P* \< 0.1). The *I*^2^ statistic was also calculated, and an *I*^2^ \> 50% indicated significant heterogeneity across studies[@b46]. A random-effects model was used if significant heterogeneity was shown among the trials. Otherwise, the results were obtained from a fixed-effects model. To provide more information on the data synthesis, we showed the results calculated from both the two models.

We excluded percent changes in mean and SD values when we extracted data for the meta-analysis. SD values were calculated from standard errors, 95% CIs, *P* values, or t-statistics when they were not directly available. In addition, change-from-baseline SD values were imputed as suggested by Follmann et al[@b47], assuming a correlation coefficient of 0.5.

Publication bias was assessed with funnel plots and Egger\'s test. Previously defined subgroup analyses were performed to examine the potential source of heterogeneity within these studies and included BP status, study design, type of intervention, duration, green tea polyphenol dose, and Jadad score. Additional sensitivity analyses were also performed according to the Handbook for Systematic Review of Interventions of Cochrane software (Version 5.0.2; The Cochrane Collaboration, Oxford, United Kingdom).

Author Contributions
====================

Conceived and designed the experiments: X.L.P., K.L. and M.T.M. Analyzed the data: X.L.P., R.Z. and K.L. Contributed reagents/materials/analysis tools: X.L.P., K.L., R.Z., X.P.Y., X.H.Y. and M.T.M. Wrote the first draft of the manuscript: X.L.P., R.Z. and K.L. Reviewed, edited and approved the manuscript: X.L.P., R.Z., B.W., K.L. and M.T.M.

Supplementary Material {#s1}
======================

###### Supplementary Information

Supplementary information

This study was supported by the "12th Five year Plan" for National Key Technology Research and Development Program (grant number: 2012BAI35B02).

![Flow diagram showing the number of citations retrieved by individual searches of articles included in the review.](srep06251-f1){#f1}
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###### Characteristics of 13 randomized controlled trials included in analysis

  Source                              No. of subjects   Study design                               Population                                Duration                           Tea group                                             Control group                      Jadad score   Type of diet[a](#t1-fn2){ref-type="fn"}
  ---------------------------------- ----------------- -------------- --------------------------------------------------------------------- ---------- ----------------------------------------------------------- ---------------------------------------------------- ------------- -----------------------------------------
  Fukino, 2005, Japan (11)                  66            Parallel              Stage 1 hypertension, overweight, 32--73 y of age              2 mo                     DGTB (544 mg polyphenols)                                         No tea                             \<4                     Usual diet
  Diepvens, 2006, Netherlands (12)          46            Parallel                Prehypertension, overweight, 19--57 y of age                 87 d       GTE capsule (1,207 mg polyphenols, 236.7 mg caffeine)               Placebo (maltodextrin capsule)                 \<4                   Low-energy diet
  Nagao, 2007, Japan (13)                   240           Parallel                   Prehypertension, obese, 25--55 y of age                  12 wk       GTE beverage (582.8 mg polyphenols, 72.3 mg caffeine)      GTE beverage (96 mg catechins, 75.0 mg caffeine)        \<4                     Usual diet
  Hill, 2007, Switzerland (14)              38            Parallel             Prehypertension, overweight/obese, 45--70 y of age             12 wk                 DGTE capsule (300 mg polyphenols)                           Placebo (lactose capsules)                   \<4               Usual diet with excise
  Fukino, 2008, Japan (15)                  70           Crossover              Stage 1 hypertension, overweight, 32--73 y of age              2 mo        GTE beverage (544 mg polyphenols, 102 mg caffeine)                             Water                              \<4                     Usual diet
  Nagao, 2009, Japan (16)                   43            Parallel                 Prehypertension, T2DM, 64.9 ± 1.6 y of age                 12 wk       GTE beverage (582.8 mg polyphenols, 72.3 mg caffeine)     GTE beverage (96.3 mg catechins, 75.0 mg caffeine)       \<4                     Usual diet
  Frank, 2009, UK (17)                      33            Parallel                 Prehypertension, overweight,18--55 y of age                 3 wk         GTE Capsule (714 mg polyphenols, 114 mg caffeine)                     Placebo (maltodextrin)                     \<4                     Usual diet
  Brown, 2009, UK (18)                      88            Parallel             Prehypertension, overweight/obese, 40--65 y of age              8 wk                 DGTE capsule (800 mg polyphenols)                           Placebo (lactose capsules)                   ≥4                      Usual diet
  Nantz, 2009, USA (19)                     111           Parallel                Prehypertension, overweight, 21--70 y of age                 3 mo                     DGTB (320 mg polyphenols)                                    Placebo capsule                         ≥4                      Usual diet
  Basu, 2010, USA (20)                      22            Parallel     BP \< 160/100 mmHg, obesity and metabolic syndrome, 25--63 y of age     8 wk     Green tea beverage (928 mg polyphenols, 8.96 mg caffeine)                         Water                              \<4                     Usual diet
  Brown, 2011, UK (21)                      66           Crossover           Prehypertension, overweight and obese, 40--69 y of age            6 wk                 DGTE capsule (800 mg polyphenols)                           Placebo (lactose capsules)                   ≥4                      Usual diet
  Suliburska, 2012, Poland (22)             46            Parallel                   Prehypertension, obese, 30--60 y of age                   3 mo                 DGTE capsule (208 mg polyphenols)                          Placebo capsules (cellulose)                  ≥4                      Usual diet
  Bogdanski, 2012, Poland (23)              56            Parallel                Stage 1 hypertension, obese, 30--60 y of age                 3 mo                 DGTE capsule (208 mg polyphenols)                          Placebo capsules (cellulose)                  ≥4                      Usual diet

Abbreviations: DGTB, Decaffeinated green tea beverage; DGTE, decaffeinated green tea extract; EGCG, epigallocatechin gallat; GTE, green tea extract; T2DM, type 2 diabetes mellitus.

*^a^*A usual diet was similar to a conventional diet; a low-energy diet contained less amounts of energy than a usual diet.

###### Subgroup analyses of blood pressure (BP) stratified by previously defined study characteristics

                                                      Systolic blood pressure (SBP)           Diastolic blood pressure (DBP)                                                                                                               
  -------------------------------------------------- ------------------------------- ------------------------------------------------- ------ --------- --------- ---- ------------------------------------------------- ------- --------- ---------
  BP status                                                                                                                                                                                                                                     
  Stage 1hypertension                                               3                 −3.52 (−5.61, −1.43)[a](#t2-fn1){ref-type="fn"}   0.30    16.2      0.001    3    −4.30 (−5.99, −2.60)[a](#t2-fn1){ref-type="fn"}   0.81    \<0.001   \<0.001
                                                                                      −3.56 (−5.65, −1.47)[b](#t2-fn2){ref-type="fn"}                     0.006         −4.30 (−5.99, −2.60)[b](#t2-fn2){ref-type="fn"}                     \<0.001
  Prehypertension                                                   9                 −1.57 (−2.66, −0.48)[a](#t2-fn1){ref-type="fn"}   0.56   \<0.001    0.005    9    −1.33 (−2.11, −0.56)[a](#t2-fn1){ref-type="fn"}   0.05     49.3      0.001
                                                                                      −1.57 (−2.66, −0.48)[b](#t2-fn2){ref-type="fn"}                     0.005         −1.96 (−3.53, −0.39)[b](#t2-fn2){ref-type="fn"}                      0.012
  Study design                                                                                                                                                                                                                                  
  Parallel                                                         11                 −2.82 (−3.95, −1.69)[a](#t2-fn1){ref-type="fn"}   0.95   \<0.001   \<0.001   11   −2.52 (−3.33, −1.70)[a](#t2-fn1){ref-type="fn"}   0.29     15.9     \<0.001
                                                                                      −2.82 (−3.95, −1.69)[b](#t2-fn2){ref-type="fn"}                    \<0.001        −2.39 (−3.37, −1.41)[b](#t2-fn2){ref-type="fn"}                     \<0.001
  Crossover                                                         2                  0.31 (−1.54, 2.16)[a](#t2-fn1){ref-type="fn"}    0.97   \<0.001    0.743    2     0.05 (−1.33, 1.43)[a](#t2-fn1){ref-type="fn"}    0.04     76.0      0.942
                                                                                       0.31 (−1.54, 2.16)[b](#t2-fn2){ref-type="fn"}                      0.743         −2.20 (−8.49, 4.10)[b](#t2-fn2){ref-type="fn"}                       0.494
  Type of intervention                                                                                                                                                                                                                          
  Trials ruling out confounding effect of caffeine                  9                 −2.00 (−2.99, −1.01)[a](#t2-fn1){ref-type="fn"}   0.19    28.8     \<0.001   9    −1.84 (−2.56, −1.12)[a](#t2-fn1){ref-type="fn"}   0.01     63.0     \<0.001
                                                                                      −2.04 (−3.31, −0.77)[b](#t2-fn2){ref-type="fn"}                     0.002         −1.89 (−3.24, −0.54)[b](#t2-fn2){ref-type="fn"}                      0.006
  Trials using green tea contained caffeine                         4                 −1.55 (−5.84, 2.75)[a](#t2-fn1){ref-type="fn"}    0.89   \<0.001    0.481    4    −2.16 (−5.36, 1.05)[a](#t2-fn1){ref-type="fn"}    0.23     30.5      0.187
                                                                                      −1.55 (−5.84, 2.75)[b](#t2-fn2){ref-type="fn"}                      0.481         −2.15 (−6.06, 1.76)[b](#t2-fn2){ref-type="fn"}                       0.281
  Duration                                                                                                                                                                                                                                      
  \<12 wk (low median)                                              5                 −0.44 (−1.97, 1.09)[a](#t2-fn1){ref-type="fn"}    0.59   \<0.001    0.575    5    −0.79 (−1.90, 0.32)[a](#t2-fn1){ref-type="fn"}    0.02     65.3      0.161
                                                                                      −0.44 (−1.97, 1.09)[b](#t2-fn2){ref-type="fn"}                      0.575                       −1.60 (−4.16, 0.96)                                    0.220
  ≥12 wk (low median)                                               8                 −2.98 (−4.21, −1.74)[a](#t2-fn1){ref-type="fn"}   0.91   \<0.001   \<0.001   8    −2.57 (−3.48, −1.66)[a](#t2-fn1){ref-type="fn"}   0.29     17.2     \<0.001
                                                                                      −2.98 (−4.21, −1.74)[b](#t2-fn2){ref-type="fn"}                    \<0.001        −2.43 (−3.54, −1.32)[b](#t2-fn2){ref-type="fn"}                     \<0.001
  Green tea polyphenols dose                                                                                                                                                                                                                    
  \<582.8 mg/d (low median)                                         6                 −2.87 (−4.23, −1.51)[a](#t2-fn1){ref-type="fn"}   0.55   \<0.001   \<0.001   6    −3.19 (−4.20, −2.18)[a](#t2-fn1){ref-type="fn"}   0.44    \<0.001   \<0.001
                                                                                      −2.87 (−4.23, −1.51)[b](#t2-fn2){ref-type="fn"}                    \<0.001        −3.19 (−4.20, −2.18)[b](#t2-fn2){ref-type="fn"}                     \<0.001
  ≥582.8 mg/d (high median)                                         7                 −1.08 (−2.44, 0.29)[a](#t2-fn1){ref-type="fn"}    0.60   \<0.001    0.122    7    −0.60 (−1.58, 0.37)[a](#t2-fn1){ref-type="fn"}    0.23     25.9      0.227
                                                                                      −1.08 (−2.44, 0.29)[b](#t2-fn2){ref-type="fn"}                      0.122         −0.79 (−2.11, 0.54)[b](#t2-fn2){ref-type="fn"}                       0.244
  Jadad score                                                                                                                                                                                                                                   
  Low (\<4)                                                         8                 −1.76 (−3.92, 0.40)[a](#t2-fn1){ref-type="fn"}    0.97   \<0.001    0.110    8    −1.17 (−2.67, 0.32)[a](#t2-fn1){ref-type="fn"}    0.47    \<0.001    0.125
                                                                                      −1.76 (−3.92, 0.40)[b](#t2-fn2){ref-type="fn"}                      0.110         −1.17 (−2.67, 0.32)[b](#t2-fn2){ref-type="fn"}                       0.125
  High (≥4)                                                         5                 −2.03 (−3.10, −0.96)[a](#t2-fn1){ref-type="fn"}   0.04    60.7     \<0.001   5    −2.04 (−2.84, −1.25)[a](#t2-fn1){ref-type="fn"}   0.001    78.1     \<0.001
                                                                                      −2.15 (−3.94, −0.36)[b](#t2-fn2){ref-type="fn"}                     0.019         −2.20 (−4.06, −0.35)[b](#t2-fn2){ref-type="fn"}                      0.020

*^a^*The result was obtained from a fixed-effects model.

*^b^*The result was obtained from a random-effects model.
